Prime Medicine
40 articles about Prime Medicine
-
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
3/1/2024
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.
-
Prime Medicine to Participate in Upcoming March 2024 Investor Conferences
2/28/2024
Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced that company management will participate in two upcoming conferences.
-
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2/20/2024
Prime Medicine, Inc. announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock.
-
Prime Medicine Announces Pricing of Upsized Public Offering - February 15, 2024
2/15/2024
Prime Medicine, Inc. announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant.
-
Prime Medicine Announces Proposed Public Offering of Common Stock - February 14, 2024
2/14/2024
Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock.
-
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
1/25/2024
Prime Medicine, Inc. (Nasdaq: PRME) today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF).
-
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
1/5/2024
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.
-
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Prime Medicine, Inc. (Nasdaq: PRME) today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m. ET) in San Francisco, CA.
-
Prime Medicine to Present at Upcoming November 2023 Investor Conferences
11/8/2023
Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, announced that company management will present at two upcoming investor conferences..
-
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/3/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
-
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
10/27/2023
Prime Medicine, Inc. reported new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct one of the most prevalent disease-causing mutations of glycogen storage disease 1b in non-human primates and mouse models.
-
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
10/24/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP).
-
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
10/17/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime Editing pipeline and platform at several healthcare industry conferences in October and November 2023.
-
Prime Medicine to Present at Upcoming Investor Conferences - September 19, 2023
9/19/2023
Prime Medicine, Inc. announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences:
-
Prime Medicine to Present at Upcoming September 2023 Investor Conferences
8/31/2023
Prime Medicine, Inc. announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two upcoming investor conferences.
-
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
8/7/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the second quarter ended June 30, 2023.
-
Gene editing technologies are advancing rapidly in the clinic, with the potential first approval later this year, but challenges remain.
-
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
6/22/2023
Prime Medicine, Inc. and Cimeio Therapeutics announced a research collaboration to combine their respective technologies, including Prime Medicine’s Prime Editing platform and Cimeio’s Shielded Cell and Immunotherapy Pairs platform.
-
Prime Medicine to Present at Investor Conferences in June 2023
5/31/2023
Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in three investor conferences in June.
-
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
5/17/2023
Prime Medicine, Inc. announced the presentation of new preclinical data that further demonstrated the potential of Prime Editing to correct the causative mutation of chronic granulomatous disease and preclinical data that showcased the potential application of the Prime Editing Assisted Site-Specific Integrase Gene Editing platform to generate multiplex-edited CAR-T cells for the treatment of certain cancers and immune diseases.